Google
PLYX — POLARYX THERAPEUTICS, INC. COMMON STOCK (Healthcare >> Biotechnology)
PLYX FAQ
What is PLYX's ROE?
POLARYX THERAPEUTICS, INC. COMMON STOCK reports a Return on Equity (ROE) of -260.33%.
What is PLYX's dividend yield?
POLARYX THERAPEUTICS, INC. COMMON STOCK offers a dividend yield of 0.00%.
What is PLYX's Deepscope Quality Score?
Deepscope rates PLYX's overall financial quality at 38 out of 100, based on profitability, growth, debt and earnings stability.
Is now a good time to buy PLYX?
Deepscope's AI Timing Score for PLYX is 26 out of 100, indicating the relative attractiveness of buying at the current price using technical and momentum signals.
Which sector does PLYX belong to?
POLARYX THERAPEUTICS, INC. COMMON STOCK is classified under the Healthcare >> Biotechnology sector on the NASDAQ exchange.
|
USD 2.34
Price
-0.03
(-1.27%)
Day Change
|
|
|---|
PLYX, the overall quality is not good ( Quality = 38) and the timing to buy is ...(Sign In to See)...
Loading chart...
- Signal
- UNDERPERFORM
- Signal Description
- Company financial health is Not Good
- Reason
-
ROE is relatively low.
ROA is relatively low.
Historical ROE is relatively low
ROE is decreasing significantly
ROA is too relatively low compare to ROE
Current growth of ROA was below our criteria.
Net profit margin is relatively low.
Acceleration of net profit margin growth rate is below our criteria
88 Sign in
TIMING
- Signal
- OUTPERFORM
- Signal Descri...
- Good
- Reason
- Lorem ipsum dolor sit amet
In details, quality factors are not good , financial health is not quite good , and ability to make profit is not good , ...
| Quality Factors |
|
44% |
| In Recommendations? | Not in any sections |
| Select Rate | 0.00 From 30 days period |
| Watch Rate | 0.00 From 30 days period |
| News Score | 89 |
| Magic Formula Rank by ROA |
N/A
|
| Magic Formula Rank by ROE |
N/A
|
| Magic Formula Rank by ROIC |
N/A
|
| Price | 2.34 |
| PBV / Sector |
47.48 / 4.90
|
| Earning Per Share | -0.13 |
| PE / Sector |
N/A / 18.25
|
| PEG or PE/Growth / Sector |
N/A / 0.62
|
| Average 1M Daily Value |
1.11 M
GREAT
|
| Average 1W Daily Value |
0.34 M
GREAT
|
| Timing Factors |
|
42% |
| Financial Health |
|
50% |
| Ability to Make Profit |
|
37% |
| Return to Investors |
|
8% |
| Registration Details |
| Analyze Date | 2026-06-16 09:59:10 |
| Symbol | PLYX |
| Name | POLARYX THERAPEUTICS, INC. COMMON STOCK |
| Sector | Healthcare >> Biotechnology |
| Market | NASDAQ |
| Listed Shares | 49.85 M |
| Par Value | N/A |
| Calculated From | Quarter |
| Sign | N/A |
| Market Cap (M.USD) / Sector Average | 118.13 / 8,995.97 |
| News, Concensus, ... |
| Estimation Consensus | See at WSJ.com |
| Full details | See at WSJ.com |
| Chart | See in Chart feature |
| News | See at Yahoo Finance |
Address: South Tower, Paramus, NJ, United States, 07652
Phone: 201 940 7236
Website: https://polaryx.com
Sector: Healthcare >> Biotechnology
Description: Polaryx Therapeutics, Inc., a clinical-stage biotechnology company, engages in the discovery, development, and commercialization of disease-modifying therapies for rare and pediatric lysosomal storage disorders in the United States. Its pipeline includes PLX-100, a preclinical stage orally administrable combination therapy; PLX-200, a repurposed oral small molecule for the treatment of LSDs; PLX-300, a preclinical stage orally administrable combination therapy; and PLX-400, a preclinical stage novel gene therapy candidate. The company was founded in 2014 and is based in Paramus, New Jersey.
ME vs SECTOR Healthcare >> Biotechnology
Click a bubble to view stock details · Bubble size represents market capitalization share
